Skip to main content
Article thumbnail
Location of Repository

A laminar flow model of aerosol survival of epidemic and non-epidemic strains of Pseudomonas aeruginosa isolated from people with cystic fibrosis

By I.J. Clifton, L.A. Fletcher, Clive B. Beggs, M. Denton and D.G. Peckham


Cystic fibrosis (CF) is an inherited multi-system disorder characterised by chronic airway infection with pathogens such as Pseudomonas aeruginosa.\ud Acquisition of P. aeruginosa by patients with CF is usually from the environment, but recent studies have demonstrated patient to patient transmission of certain epidemic strains, possibly via an airborne route. This study was designed to examine the survival of P. aeruginosa within artificially generated aerosols.\ud Survival was effected by the solution used for aerosol generation. Within the aerosols it was adversely affected by an increase in air temperature. Both epidemic and non-epidemic strains of P. aeruginosa were able to survive within the aerosols, but strains expressing a mucoid phenotype had a survival advantage.\ud This would suggest that segregating individuals free of P. aeruginosa from those with chronic P. aeruginosa infection who are more likely to be infected with mucoid strains may help reduce the risk of cross-infection. Environmental factors also appear to influence bacterial survival. Warming and drying the air within clinical areas and avoidance of humidification devices may also be beneficial in reducing the risk of cross-infection

Topics: Laminar Flow, Aerosols, Survival, Pseudomonas aeruginosa, Cystic Fibrosis
Year: 2008
OAI identifier:
Provided by: Bradford Scholars

Suggested articles


  1. (1994). A: Airborne dissemination of Burkholderia (Pseudomonas) cepacia from adult patients with cystic fibrosis. Thorax doi
  2. (2002). AK: Increased treatment requirements of patients with cystic fibrosis who harbour a highly transmissible strain of Pseudomonas aeruginosa. Thorax doi
  3. (1999). al.: Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. doi
  4. (2002). Analysis of transmission pathways of Pseudomonas aeruginosa between patients and tap water outlets. Crit Care Med doi
  5. (2005). CA: Environmental contamination with an epidemic strain of Pseudomonas aeruginosa in a Liverpool cystic fibrosis centre, and study of its survival on dry surfaces. J Hosp Infect doi
  6. (2001). Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. doi
  7. (1996). Distribution and transmission of Pseudomonas aeruginosa and Burkholderia cepacia in a hospital ward. Pediatr Pulmonol doi
  8. (1997). Effect of aerosolization on culturability and viability of gram-negative bacteria. Appl Environ Microbiol
  9. (2002). et al.: Transmission of colistin-resistant Pseudomonas aeruginosa between patients attending a pediatric cystic fibrosis center. Pediatr Pulmonol doi
  10. (2003). Evidence for spread of a clonal strain of Pseudomonas aeruginosa among cystic fibrosis clinics. doi
  11. (2002). GB: Lung infections associated with cystic fibrosis. Clin Microbiol Rev doi
  12. (1991). Generation of Pseudomonas aeruginosa aerosols during handwashing from contaminated sink drains, transmission to hands of hospital personnel, and its prevention by use of a new heating device. Zentralbl Hyg Umweltmed
  13. (2006). GL: Factors involved in the aerosol transmission of infection and control of ventilation in healthcare premises. J Hosp Infect doi
  14. (1997). Hoiby N: Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol doi
  15. (1990). Hoiby N: Pseudomonas aeruginosa alginate in cystic fibrosis sputum and the inflammatory response. Infect Immun
  16. (2003). Identification of airborne dissemination of epidemic multiresistant strains of Pseudomonas aeruginosa at a CF centre during a cross infection outbreak. Thorax doi
  17. (1995). Inertial samplers: biological perspectives.
  18. (1999). Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. doi
  19. (1991). Medical and microbiological problems arising from airborne infection in hospitals. doi
  20. (1992). Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol doi
  21. (1958). New sampler for the collection, sizing, and enumeration of viable airborne particles.
  22. (1934). On air-borne infection. II. Droplets and droplet nuculei.
  23. (1989). Positive-hole correction of multiple-jet impactors for collecting viable microorganisms. doi
  24. (1993). Regelmann WE: Prognostic implications of initial oropharyngeal bacterial flora in patients with cystic fibrosis diagnosed before the age of two years. doi
  25. (1977). Reservoirs of Pseudomonas aeruginosa in an intensive care unit for newborn infants: mechanisms of control. doi
  26. Saiman L: Measurement of bac- doi
  27. (2005). Saiman L: Measurement of bacterial shedding in CF clinics. Pediatric Pulmonology
  28. (2001). Stanbridge TN, et al.: Spread of a multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic. Lancet doi
  29. (2003). The airborne transmission of infection in hospital buildings: fact or fiction? Indoor and Built Environment doi
  30. (1973). The Collison nebulizer: Description, performance and application. Aerosol Science doi
  31. (2004). Walshaw MJ: Increased morbidity associated with chronic infection by an epidemic Pseudomonas aeruginosa strain in CF patients. Thorax doi
  32. (2001). Walshaw MJ: Superinfection with a transmissible strain of Pseudomonas aeruginosa in adults with cystic fibrosis chronically colonised by P. aeruginosa. Lancet doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.